Analysis
The GLP-1 shortage timeline and what it meant for compounding
Branded GLP-1 shortages during 2022–2024 opened the door to large-scale compounding, which is why so many cash-pay programs appeared. As the FDA decla
Branded GLP-1 shortages during 2022–2024 opened the door to large-scale compounding, which is why so many cash-pay programs appeared. As the FDA declared the shortages resolved on molecule-specific timelines, the legal basis for mass compounding narrowed and enforcement attention increased.
The full picture
Compounding is broadly permitted when an approved drug is in shortage. The Wegovy/Ozempic and Mounjaro/Zepbound shortages created exactly that condition, and a wave of compounded semaglutide and tirzepatide followed at aggressive cash-pay prices.
The turn came as the FDA moved each molecule off its shortage list. Semaglutide and tirzepatide came off on their own timelines, and with that, the shortage-based justification for mass compounding weakened, with transition periods and enforcement — including on semaglutide salt forms — following.
The market that remains has shifted toward transparent, membership-free pricing. The durable lesson from the shortage era is that headline prices moved far more than effective prices ever did.
Frequently asked questions
Why was compounded GLP-1 so available?
Branded shortages permitted large-scale compounding.
What changed?
The FDA declared the shortages resolved, narrowing the basis for mass compounding.
Related: evidence database · cost calculator · semaglutide · tirzepatide.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.